213 related articles for article (PubMed ID: 10490729)
1. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
Vogelsang G; Bitton R; Piantadosi S; Altomonte V; Horn T; Jones R; Miller C; Marcellus D; Abrams R; Hess A
Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
[TBL] [Abstract][Full Text] [Related]
2. The treatment of relapsed or refractory intermediate grade non-Hodgkin's lymphoma with autologous bone marrow transplantation followed by cyclosporine and interferon.
Gryn J; Johnson E; Goldman N; Devereux L; Grana G; Hageboutros A; Fernandez E; Constantinou C; Harrer W; Viner E; Goldberg J
Bone Marrow Transplant; 1997 Feb; 19(3):221-6. PubMed ID: 9028549
[TBL] [Abstract][Full Text] [Related]
3. Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy.
Massumoto C; Benyunes MC; Sale G; Beauchamp M; York A; Thompson JA; Buckner CD; Fefer A
Bone Marrow Transplant; 1996 Mar; 17(3):351-6. PubMed ID: 8704686
[TBL] [Abstract][Full Text] [Related]
4. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K; Margolin K; Champlin R; Forman S
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporine-induced autologous graft-versus-host disease in patients with acute myeloid leukemia undergoing non-myeloablative chemotherapy without progenitor cell reinfusion.
Stein M; Feldman E; Seiter K; Chiao JW; Goff H; Baskind P; Beer M; Ahmed T
Bone Marrow Transplant; 1999 Nov; 24(10):1073-7. PubMed ID: 10578157
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
8. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia.
Park J; Lee MH; Lee HR; Park SH; Lee SH; Lee KE; Lee H; Park JO; Kim K; Jung CW; Im YH; Kang WK; Ko YH; Park K
Bone Marrow Transplant; 2003 Nov; 32(9):889-95. PubMed ID: 14561989
[TBL] [Abstract][Full Text] [Related]
9. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.
Talbot DC; Powles RL; Sloane JP; Rose J; Treleaven J; Aboud H; Helenglass G; Parikh P; Smith C; Rowley M
Bone Marrow Transplant; 1990 Jul; 6(1):17-20. PubMed ID: 2202461
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
12. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution.
Sanz GF; Saavedra S; Jiménez C; Senent L; Cervera J; Planelles D; Bolufer P; Larrea L; Martín G; Martínez J; Jarque I; Moscardó F; Plumé G; Andreu R; de la Rubia J; Barragán E; Solves P; Soler MA; Sanz MA
Bone Marrow Transplant; 2001 Apr; 27(7):693-701. PubMed ID: 11360108
[TBL] [Abstract][Full Text] [Related]
13. New conditioning regimens for high risk marrow transplants.
Jones RJ; Santos GW
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
[TBL] [Abstract][Full Text] [Related]
14. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
15. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma.
Reynolds C; Ratanatharathorn V; Adams P; Braun T; Silver S; Ayash L; Carson E; Eisbruch A; Dawson LA; McDonagh K; Ferrara J; Uberti J
Bone Marrow Transplant; 2001 Apr; 27(8):801-7. PubMed ID: 11477436
[TBL] [Abstract][Full Text] [Related]
17. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
18. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Saito T; Kanda Y; Kami M; Kato K; Shoji N; Kanai S; Ohnishi T; Kawano Y; Nakai K; Ogasawara T; Matsubara H; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Clin Cancer Res; 2002 Apr; 8(4):1014-20. PubMed ID: 11948108
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-host disease after autologous bone marrow transplantation: a realistic expectation?
Niederwieser D; Eibl B; Nachbaur D
Wien Med Wochenschr; 1995; 145(2-3):25-7. PubMed ID: 7762248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
